Enhertu for Secondary Breast Cancer: Science and Stories
Trastuzumab deruxtecan (Enhertu®) is used to treat certain secondary breast cancers. This blog delves into the science while looking at the real experiences of patient’s on this drug.
What is HER2-low Breast Cancer?
HER2-low is a new way to characterise breast cancer. In short, many previously considered HER2-negative breast cancer patients can now be considered HER2-low. This provides a new treatment target for many secondary (metastatic, advanced) breast cancers.